Ocugen Inc (OCGN) stock is lower by 15.71% over the past week and gets a Bullish rating from InvestorsObserver's Sentiment Indicator.
What is Stock Sentiment?
Sentiment uses short term technical analysis to gauge whether a stock is desired by investors. As a technical indicator, it focuses on recent trends as opposed to the long term health of the underlying company. Updates for the company such as a earnings release can move the stock away from current trends.
Sentiment is how investors, or the market, feels about a stock. There are lots of ways to measure sentiment. At the core, sentiment is pretty easy to understand. If a stock is going up, investors must be bullish, while if it is going down, sentiment is bearish.
InvestorsObserver’s Sentiment Indicator looks at price trends over the past week and also considers changes in volume. Increasing volume can mean a trend is getting stronger, while decreasing volume can mean a trend is nearing a conclusion.
For stocks that have options, our system also considers the balance between calls, which are often bets that the price will go up, and puts, which are frequently bets that the price will fall.
What's Happening With OCGN Stock Today?
Ocugen Inc (OCGN) stock is trading at $2.36 as of 3:33 PM on Thursday, Jan 14, a loss of -$0.14, or -5.8% from the previous closing price of $2.50. The stock has traded between $2.25 and $2.44 so far today. Volume today is light. So far 15,912,115 shares have traded compared to average volume of 90,763,088 shares.
To see InvestorsObserver's Sentiment Score for Ocugen Inc click here.
More About Ocugen Inc
Ocugen Inc is a clinical-stage biopharmaceutical company. It is focused on discovering, developing and commercializing a pipeline of innovative therapies that address rare and underserved eye diseases. Ocugen offers a diversified ophthalmology portfolio that includes novel gene therapies, biologics, and small molecules and targets a broad range of high-need retinal and ocular surface diseases. Its product candidate includes OCU200 and OCU300 to treat diabetic macular edema (DME), diabetic retinopathy (DR) and wet age-related macular degeneration (AMD).
Click Here to get the full Stock Score Report on Ocugen Inc (OCGN) Stock.
